The drug market for chronic spontaneous urticaria (CSU), previously know as chronic idiopathic urticaria, is dominated by oral medications, including first- and second-generation (nondrowsy) antihistamines, off-label DMARDs, immunosuppressants, and tricyclic antidepressants. However, several drug classes have serious side effects, and many patients still struggle to control their lesions. As a result, the approval of Novartis / Roche’s Xolair was welcomed, but the high cost limits access for many patients. Guidelines for CSU were recently updated to remove montelukast and prioritize prescription therapies, but some physicians have been slow to adapt.
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.